Fagron is happy to announce that SyrSpend® SF is currently being recognized by large pharmaceutical companies for its quality and compatibility, as is demonstrated by the fact that two big pharmaceutical companies are using the product for their clinical
The European Commission (EC) announced the public consultation on methylisothiazolinone (MI) in rinse-off cosmetic products proposing a restriction of its use and a ban for the use in leave-on products.
For patients that require non-standard doses, experience swallowing difficulties or receive medication via enteral feeding tubes, compounding oral liquid dosage forms is common and important pharmacy practice.
There is an increasing interest for Pentravan® transdermal cream in scientific literature. A new publication in the most recent edition of the International Journal of Pharmaceutical Compounding concludes that human female sexual hormones incorporated in
Over 200 unique compounding instructions for more than 120 different active pharmaceutical ingredients (APIs) in Fagron’s global Advanced Derma and SyrSpend® SF bases have been uploaded to the Compounding Matters database.
Pentravan® (penetration enhanced vanishing cream) is a transdermal delivery system for drugs (active pharmaceutical ingredients; APIs) and is intended for use as a cream base for pharmaceutical compounding.
Fagron Group announces today that it has signed an agreement for the acquisition of Polish company Pharma Cosmetic, a leading supplier of pharmaceutical raw materials for compounding pharmacies in Poland.
Fagron Group announces today that it has signed an agreement for the acquisition of the Brazilian Pharma Nostra, a leading supplier of raw materials for pharmaceutical compounding to pharmacies in Brazil.
Fagron announces today that it has signed an agreement for the acquisition of the Dutch Pharma Cosmetic, a compounding pharmacy that specializes in preparing tailor-made aseptic and high risk compounded products for individual patients.
The US Food and Drug Administration (FDA) has approved that, in the event of a shortage of Tamiflu®1/Oseltamivir oral suspension for children, pharmacists should revert to emergency compounding, using Ora-Sweet SF® or Humco Cherry Syrup®.